Unravel RWD with Advanced Analytical Frameworks to Strategically Prepare for Commercial Biosimilar Launch
Description
In the epoch of thriving Biosimilars launch phase, ever wondered why they haven’t been as successful as their reference Biologic product? The conventional brand launch strategies fail when it comes to Biosimilar launches as there is a huge gap in terms of awareness about Biosimilar products & Bioequivalence, Targeting, and Messaging. Therefore, it is important for the Pharma companies to understand the key drivers and the associated stakeholders that determine the success of a Biosimilar launch.
In this webinar, we will be discussing how to leverage RWD to build robust analytical framework for targeting the most influential stakeholders and positioning the Biosimilar for a strategic commercial launch.
Janani is Consultant at D Cube Analytics, she comes with 6+ years of experience in supporting Market Planning and Brand teams with analytical solutions to make strategic data driven decisions. She has extensively worked on Oncology, Neuro and Immunology therapeutic areas covering a spectrum of business problems - Pre/Post Drug Launch Strategic Analysis, Patient Chart Audits, Physician-level data analytics, Sales Force Effectiveness and Primary Market Research
Daniel is an Associate Consultant at D Cube Analytics, who has around 5+ years of experience in supporting the analytical needs of the regional and global brand teams in their quest towards building-up next-gen strategies across launch and pre-launch space. He brings in expertise on the Inflammation therapeutic area and has solved business problems pertaining to sales and commercial analytics, Payer and Provider analytics, and also Patient treatment dynamics by leveraging syndicated data sources and extensive market research.
Presenters:
- Janani Damodaran, Consultant at D Cube Analytics
- Daniel Britto, Associate Consultant at D Cube Analytics